Fundz

Lantern Pharma Inc. Secures Funding Through Registered Direct Offering

PUBLIC · LTRNSep 28, 2026

Amount Raised

$1.6 Million

Round Type

Post-IPO Equity

DallasBiotechnology

Description

On September 28, 2026, Lantern Pharma Inc. entered into a securities purchase agreement with an institutional investor, agreeing to issue shares and warrants in a registered direct offering. The closing of this offering occurred on September 30, 2026. This funding will support the company's ongoing efforts in developing cancer therapies

Company Information

Company

Lantern Pharma

Location

1920 MCKINNEY AVENUE

Dallas, Georgia, United States

About

Lantern develop novel targeted cancer therapeutics.

Fundz sees it the moment Lantern Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Lantern Pharma's next move

See what Strategic adds

Lantern Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.